The collection of carefully characterised samples is of paramount importance to the delivery of robust biomarkers. Through our pedigree as the world’s leading epigenetics technology company, we have built close relationships with distinguished clinical research institutions worldwide, extending our knowledge base and providing unrivalled access to well-characterised sample collections for biomarker development. Every sample undergoes rigorous quality assessment with full reports to enable the generation of meaningful results. Our proprietary epigenetic analysis technologies have been proven to work with sample amounts as low as 1 ng, allowing sensitive detection of epigenetic DNA modifications from all sample types including cell-free DNA (cfDNA) and circulating tumour DNA (ctDNA) from liquid biopsy samples.
We are utilising our disruptive discovery platform and the power of the epigenetic modification 5hmC to develop improved, minimally invasive liquid biopsy diagnostic assays for a number of important diseases with unmet needs. We also partner with leading researchers and biopharma companies to accelerate the benefits of epigenetic-based medicine to improve human health.
Utilising the power of 5hmC to develop minimally invasive diagnostic assays for diseases with significant unmet need.
Our diagnostic development process
In addition to our in-house diagnostic development programs, we partner with selected biopharma companies to accelerate the benefits of epigenetic medicine.
Our project teams are assembled based on the specific needs of each individual biomarker development programme and draw on in-house expertise as well as our global network of collaborators. We develop and utilise the most cutting-edge epigenetic sequencing technologies for all of our diagnostic discovery projects.
Sample collection and preparation
At Cambridge Epigenetix, sequencing is literally in our DNA. The company was founded by Professor Sir Shankar Balasubramanian, co-inventor of the world’s leading high-throughput sequencing technology, to develop new techniques for the accurate analysis of 5hmC and other epigenetic DNA modifications. We have developed novel sequencing protocols specifically tailored to the accurate analysis of epigenetic modifications for biomarker discovery.
Our experienced Bioinformatics team is at the vanguard of epigenetic analysis and biomarker discovery. We tailor our tried-and-tested analysis pipelines that have been validated through our own in-house biomarker development programmes to suit each specific project, ensuring the delivery of robust biomarkers. Our data analysis workflows are backed up by a fully integrated, state-of-the-art technology infrastructure, which is underpinned by stringent data security procedures.
Using our automated high-throughput workflows and bioinformatics expertise, we are able to accurately and rapidly validate putative biomarkers on hundreds to thousands of samples. We optimise the number of samples required to deliver cost-effective analysis with the highest confidence in results.
Clinical development and deployment
We develop and analytically validate all of our diagnostic assays to ensure robust, comparable clinical validation results. Furthermore, our strong strategic relationships with selected clinical research institutions enable us to deliver full biomarker validation.
Our disruptive epigenetics discovery platform enables the identification of sensitive and disease-specific epigenetic marks from liquid biopsy and tissue samples.Our Technologies
Find Out More
Interested in working with us, or want to know more about what we do?Contact us